sn201211016k.htm
 
 
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549
 
 
Report of Foreign Private Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of

1934
 
 
November 01, 2012 
 
Commission File Number 001-14978




SMITH & NEPHEW plc
(Registrant's name)



15 Adam Street

London, England WC2N 6LA
(Address of registrant's principal executive offices)

 
[Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.]

 
Form 20-F X                Form 40-F
    ---                               ---

[Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1).]


Yes                        No X
---                         ---

 
[Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7).]

 
Yes                      No X
---                         ---

[Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing information to the
Commission pursuant to Rule 12g3-2 (b) under the Securities Exchange Act of
1934.]

 
Yes                  No X
---                   ---

 
If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b) : 82- n/a.







 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
Smith & Nephew Plc
(Registrant)
 
 
Date: November 01, 2012
 
 
By: /s/ Susan Swabey
-----------------
 
Susan Swabey
Company Secretary




 
 
Directorate Change
 
 
1 November 2012
 
 
Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, today announces that Prof. Geneviève Berger has resigned as a Non-Executive Director with effect from today.
 
Geneviève Berger, said
 
"I am sorry to be leaving Smith & Nephew at such an exciting time as the business refocuses under Olivier's leadership.  My decision reflects the demands placed on my time from my wider commitments.  I wish John, Olivier and all at Smith & Nephew the very best for the future. "
 
Sir John Buchanan, Chairman of Smith & Nephew, commented:
 
"I would like to thank Geneviève for her contribution as a Non-Executive Director and valuable member of our Ethics & Compliance Committee.  I understand her decision to concentrate her time on a more focused portfolio and she leaves with the good wishes of us all."
 
 
 
Enquiries
 
Investors
Phil Cowdy                                                                 Tel:    +44 (0) 20 7401 7646
Smith & Nephew
 
Media
Charles Reynolds                                                      Tel:    +44 (0) 20 7401 7646
Smith & Nephew
 
Justine McIlroy / Andrew Mitchell                        Tel:    +44 (0) 20 7404 5959
Brunswick - London
                                                                                                            
 
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma, Smith & Nephew has almost 11,000 employees and a presence in more than 90 countries. Annual sales in 2011 were nearly $4.3 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).
 

 
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payors and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions, our success in integrating acquired businesses, and disruption that may
result from changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business or competitive nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors.
 
Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.